Cytokinetics (CYTK) fundamentals: P/E, valuation, undervalued?
Cytokinetics · Health Care · ref. ETF XLV · price $61.62
In short — Cytokinetics trades at —× earnings (P/E), -13.9× forward, with a net margin of 0.0 % and revenue growth of -57 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Cytokinetics stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$61.62+1.0% over range
Oct 14, 25low $54.76 · high $87.26Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 13 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
-13.9
Forward P/E
—
PEG
—
Price/book (P/B)
$8.6B
Market cap
-7.22
EPS
Profitability & growth
0.0 %
Net margin
-57 %
Revenue growth
—
Earnings growth
$1.4B
Total debt
Cytokinetics income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $95M | $-389M | -411.2 % |
| 2023 | $8M | $-526M | -6988.6 % |
| 2024 | $18M | $-590M | -3191.1 % |
| 2025 | $88M | $-785M | -891.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Cytokinetics's P/E and is the stock undervalued? What's a good P/E?
Cytokinetics's P/E is — (forward -13.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Cytokinetics profitable?
Cytokinetics has a net margin of 0.0 % (EPS -7.22). The company is not (yet) profitable.
Is CYTK stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Cytokinetics? The JPI assistant answers using our backtest data.
Keep exploring Cytokinetics